Correspondence 0000950170-24-042691 from Aptevo Therapeutics Inc. (APVO)
Aptevo Therapeutics Inc.
Date: April 8, 2024 · CIK: 0001671584 · Accession: 0000950170-24-042691
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278103
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Attention: Ms. Doris Stacey Gama Ms. Laura Crotty Re: Aptevo Therapeutics Inc. Registration Statement on Form S-1, as amended File No. 333-278103
Dear Ms. Gama and Ms. Crotty:
In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-278103) of Aptevo Therapeutics Inc., filed with the Securities and Exchange Commission on March 20, 2024 and amended on March 29, 2024 (as amended, the “Registration Statement”). We respectfully request that the Registration Statement become effective as of 5:00 p.m., Eastern Time, on April 9, 2024 or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Paul Hastings LLP, by calling Sean M. Donahue at (202) 551-1704.
Very truly yours,
Aptevo Therapeutics Inc.
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
Aptevo Therapeutics Inc.
2401 4th Avenue, Suite 1050
Seattle, Washington 98121
April 8, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Ms. Doris Stacey Gama
Ms. Laura Crotty
Re: Aptevo Therapeutics Inc.
Registration Statement on Form S-1, as amended
File No. 333-278103
Dear Ms. Gama and Ms. Crotty:
In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-278103) of Aptevo Therapeutics Inc., filed with the Securities and Exchange Commission on March 20, 2024 and amended on March 29, 2024 (as amended, the “Registration Statement”). We respectfully request that the Registration Statement become effective as of 5:00 p.m., Eastern Time, on April 9, 2024 or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Paul Hastings LLP, by calling Sean M. Donahue at (202) 551-1704.
Very truly yours,
Aptevo Therapeutics Inc.
By: /s/ Marvin L. White
Marvin L. White
President and Chief Executive Officer
CC:
SoYoung Kwon, Aptevo Therapeutics Inc.
Daphne Taylor, Aptevo Therapeutics Inc.
Sean M. Donahue, Paul Hastings LLP